Much debate has centered on whether or not the standard 12-month duration of dual
antiplatelet therapy (DAPT) is still necessary postpercutaneous coronary intervention, given …

Determining the optimal duration of dual antiplatelet therapy (DAPT) following percutaneous
coronary intervention is a complex decision. Randomized controlled trials have shown that …

Heart Association guidelines on duration of dualantiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) give a class I …

To prevent recurrent ischaemic events, dual antiplatelet therapy (DAPT) is the standard of
care after percutaneous coronary intervention and in the treatment of acute coronary …

Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention with stenting requires consideration of patient characteristics, and …

The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) remains an important clinical question in interventional cardiology …

Aims The aim of this study was to evaluate benefits and risks of extending dual antiplatelet
therapy (DAPT) after percutaneous coronary intervention (PCI) in the drug-eluting stent era …

Among patients who have undergone percutaneous coronary intervention (PCI), the use of
dual antiplatelet therapy (DAPT) is associated with increased risk of bleeding, but decreased …

Evidence from studies published more than 10 years ago suggested that patients receiving
first-generation drug-eluting stents (DES) needed dual antiplatelet therapy (DAPT) for at …

Introduction Although dual antiplatelet therapy (DAPT) is routinely given to patients after
percutaneous coronary intervention (PCI) with stenting, the optimal duration is unknown …